Clinical trial
Three Months Treatment With SB683699 In Patients With Relapsing Multiple…
NCT00097331 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00097331 |
|---|---|
| Title | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis |
| Official title | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | SB683699 |
| Enrollment | 261 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Nov 23, 2004 |
| Last update posted | Apr 13, 2015 |
| Countries | Belgium, Germany, Poland, Russia, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: